ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

Crout Resigns As Director Of FDA Drugs Bureau

July 11, 1980

ODAC Votes 13:0 For Approving Perjeta

September 27, 2013

In Congress: Senate Bill Offers 13% Increase For NCI; house Provides 9%

October 8, 1999

Neulasta Reduces Incidence Of Febrile Neutropenia

February 22, 2013

In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics

April 15, 1977

In Brief: Cooperative Group Investigators Treat 10 For Every Patient In Protocols – Holland

October 31, 1975